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1. Introduction
Periodontitis is a chronic destructive condition caused by periodontopathogenic bacteria and
inflammatory response combined with immune system effects characterized by gingival
inflammation and loss of periodontal attachment and alveolar bone (Irfan et al. 2001). Host
response is modified by genetic and environmental factors such as smoking (Seymour and
Taylor, 2004), which has proven to be the very important risk factor for chronic periodontitis
in adults (Genco and Borgnakke, 2013) as well for adolescents (Heikkinen et al. 2008, Heikkinen
2011). In periodontitis host response indeed plays an important role in the destruction of
connective tissue and bone (Graves 2008). Smoking affects the immune system and impairs
host response by several mechanisms both systemically and locally in saliva and gingival
crevicular fluid (GCF). Systemically smoking increases the number of neutrophils in peripheral
blood but their ability to migrate through capillary walls is impaired (Hind et al. 1991).
Several types of inflammatory biomarkers associating both with oral diseases and systemic
diseases have been detected in saliva and GCF. These include interleukins-1β, -6 and -8 (IL-1β,
-6 and -8), tumor necrosis factor-α (TNF-α) and matrix metalloproteinases (MMP)-8 and -9
(Fox 1993, Kaufman and Lamster 2000, Seymour and Gemmell 2001, Kaufman and Lamster
2002, Miller et al. 2006, Rathanayake et al. 2012 and 2013), and tissue inhibitors (TIMP)-1 of
metalloproteinase (Seymour & Gemmel, 2001). Several studies have shown the association
between increased MMP-8 levels and chronic periodontitis (Mäntylä et al. 2006, Kraft-
Neumärker et al. 2012, Leppilahti et al. 2011). Matrix metalloproteinases (MMPs) and TIMP-1
might be candidates for monitoring periodontal status in smokers and non-smokers from oral
fluids, such as GCF and saliva. GCF has a particular role in site specific diagnosis. However,
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saliva is easy to collect and thus more practical. Saliva is mainly composed of water (98%), and
other compounds (2%) are electrolytes, glycoproteins, antibacterial compounds, and various
enzymes. This unique biological fluid has multiple functions, such as rinsing, solubilisation of
food substances, food and bacterial clearance, lubrication of soft tissues, bolus formation,
dilution of detritus, swallowing, speech and facilitation of mastication, all of which are related
to its fluid characteristics and specific components. In addition, saliva components contribute
to mucosal coating, digestion and antibacterial defence (Lee & Wong, 2009).
Periodontits is a major health problem involving 10% to 60% of population depending on
definition (Albandar and Rams 2002) and it is traditionally diagnosed clinically and by
radiographical examinations. New methods based on oral fluid inflammatory markers have
been suggested for diagnosing oral diseases and inflammation associated with systemic
diseases. However, smoking has an effect on levels of several possible diagnostic biomarker
candidates. Thus the aim of this chapter is to clarify the diagnostic meaning of oral fluid
inflammatory biomarkers in periodontitis in smoking adolescents and adults. We also discuss
systemic inflammation and possibilities to analyze it with specific biomarkers in saliva.
2. Smoking as a modifier of the host defense
Cigarette smoking is a principal modifiable environmental risk factor for periodontitis (Palmer
et al. 2005). It affects the immune system by impairing host defense by inhibiting granulocyte
function (Söder et al. 2002) and by neutrophil respiratory burst which causes oxidative stress
in tissues (Chapple and Matthews 2007). According to previous study results by Matthews et
al. (2011) cigarette smoking seems to have two-sided effect on periodontal inflammation: on
one hand smoking has an effect on oxygen depletion with tissue damage and on the other hand
it impairs the ability of neutrophils to response to subgingival periodontal bacteria.
Smoking decreases both the inflammatory infiltrate and number of dendritic cells (DCs) in
chronic gingivitis (Souto et al., 2011). In addition it seems that smoking decreases CC chemo‐
kine ligand (CCL)3 and CXC chemokine ligand (CXCL)8, while CC chemokine ligand (CCL)5
seems to be increased in chronic periodontitis (Souto et al., 2014). Impaired neutrophil
chemotaxis is observed in smokers compared to nonsmokers too (Srinivas et al. 2012). Mature
DCs are involved in the production of inflammatory cytokines and Th1/Th2/Th17 immune
responses in periodontal disease (Cutler and Jotwani, 2004; Allam et al., 2011). Nicotine seems
to play an important role in host immune modulation. DCs differentiated in the presence of
nicotine and stimulated by lipopolysaccharide induced a differentiation of naive CD4 T cells
into Th2 cells. However, DCs differentiated without nicotine and stimulated by lipopolysac‐
charide induced Th1 immune responses (Yanagita et al. 2014).
3. Effects of smoking on oral inflammatory biomarkers
Reduced neutrophil chemotaxis and impaired phagocytosis in smokers have been shown in
several studies suggesting that smokers’ periodontal defence is defective compared with non-
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smokers (Johannsen et al. 2014). This may also be reflected in GCF and salivary content of
biomarkers in smokers, which is relevant when possible point-of care diagnostic application
is considered. However, the intensity and duration of smoking may also have an effect on GCF
biomarker levels, but studies which take into consideration different smoking history are
lacking.
In a study of Stein et al. (2006), where GCF proteins were profiled by a protein chip technology,
spectral fingerprints were significantly different between smokers and non-smokers. Several
spectral peaks were detected only from GCF of smokers suggesting that some proteins are
there over-expressed and could potentially serve as biomarkers (Stein et al. 2006). Several
studies have reported that smoking either inhibits or intensifies individual biomarkers in GCF,
but contradictory findings do exist concerning some biomarkers. This underlines the effect of
differences in GCF sampling and analysing methods and other study specific factors, which
may lead to inter-study variation in detected biomarker levels
MMP-8, MMP-8/TIMP-1 ratio, IL-1B, myeloperoxidase (MPO), elastase, OPG and some
bacterial biomarkers, so called red complex species Tannerella forsythia, Porphyromonas
gingivalis, Treponema denticola, and Aggregatibacter actinomycetemcomitans have proven diag‐
nostic properties to differentiate periodontitis from healthy sites in multiple independent
studies. This has been shown both at site level in GCF samples and at patient level in saliva or
mouthrinse samples (Hernandez et al. 2010, Kraft-Neumärker et al. 2012, Leppilahti et al. 2011,
Leppilahti et al. 2014a,b, Mantyla et al. 2003, Nwhator et al. 2014, Ramseier et al. 2009,
Rathnayake et al., 2013; Sexton et al., 2011). Analyzing of multiple biomarkers simultaneously
can give even better diagnostic performance (Gursoy et al. 2011, Ramseier et al. 2009).
Nevertheless, biomarkers mentioned above have clear diagnostic properties for periodontal
diseases, but many oral fluid biomarkers exhibit large variation of detected levels in both
healthy and diseased sites ((Kraft-Neumärker et al 2012, Leppilahti et al. 2014, Mantyla et al.
2003, 2006). Modifying factors, such as smoking, may have an effect on the GCF biomarker
levels and disturb the diagnostic interpretation, if these factors are not taken into account
(Heikkinen et al. 2010, Heikkinen et al. 2012, Leppilahti et al. 2014a,b). Another reason for large
variation is caused by the nature of the periodontititis itself. Progression of periodontitis is
regarded to consist of quiescent periods followed by randomly occurring bursts of activity
(Goodson et al. 1982, Socransky et al. 1984). Large variation of levels of inflammatory bio‐
markers can also be an indication of the fluctuating characteristic of peridontitis. Inflammatory
GCF biomarker levels can be low in periodontitis sites during the quiet period, but levels can
multiply exponentially during the burst of activity (Leppilahti et al. 2014a,b, Sorsa et al. 2010,
Mäntyla et al. 2006). This means that most of GCF biomarkers do not associate with perio‐
dontitis in a linear and deterministic way, and it is the dynamics between the bursts and quiet
periods that matters (Papantonopoulos et al. 2013, Papantonopoulos et al. 2014). In addition
possible biomarker candidates may have a role in normal physiologic tissue regeneration.
Thus, biomarkers can be used as diagnostic tool only if we can define the range of physiological
levels and the cutoff for pathological bursts. One definite cutoff for a biomarker is not realistic,
however, and modifying factors should be taken into account. For example, even in stable
periodontitis sites after successful treatment MMP-8 levels are higher compared to healthy
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controls (Mäntyla et al. 200, Sorsa et al. 2010). In addition, modifying factors, such as smoking
and pregnancy, has to be taken into account (Gürsoy et al. 2008, 2010, Heikkinen et al. 2010,
Leppilahti et al. 2014).
Saliva would be a non-invasive sample material for oral and periodontal diagnostics. How‐
ever, it is less specific than GCF and should be regarded to give a more general picture of oral
health. As an example of potential diagnostic capacity of whole saliva is a study where whole
saliva periodontitis associated proteome was analysed (Salazar et al. 2013). Twenty proteins
were present in different abundance levels in the periodontally healthy subjects and perio‐
dontitis patients. And further, nineteen out of these 20 proteins showed higher intensities in
periodontitis saliva, and eight were previously reported potential periodontitis biomarkers,
among others MMP-8. Also specific protein signatures displayed characteristics of chronic
periodontitis. However, effect of smoking should also be considered when salivary or oral
rinse sample biomarker levels are analysed.
3.1. Matrix Metalloproteinase (MMP) -8
MMP-8 is the major collagenase in GCF, and point-of-care diagnostic tests have been devel‐
oped based on analysing it (Sorsa et al. 1999; Prescher et al. 2007, Mäntylä et al. 2003, 2006,
Sorsa et al. 2010). The tendency to lower MMP-8 concentrations in GCF of smokers compared
to non-smokers has been observed (Persson et al. 2003) as well as lower salivary levels of
MMP-8 in current smokers (Liede et al. 1999). This should be noticed when diagnostic use of
MMP-8 is being considered. However, the effect of smoking on GCF MMP-8 levels seems to
be two-fold. While overall MMP-8 mean level tends to be lower in GCF of smokers when
compared with non-smokers, in progressing attachment loss during the maintenance phase
the MMP-8 concentrations of smokers are at the same level as in non-smokers (Mäntylä et al.
2006; Leppilahti et al. 2014a). In these studies, when sites were explored in respect of repeatedly
substantially elevated MMP-8 concentrations during the maintenance phase, in part of
smokers’ sites MMP-8 concentrations reached the highest levels of all sampled sites. Thus,
lower level of MMP-8 in smokers’ GCF does not relate to all sites or to all smoking periodontitis
patients. For this reason when MMP-8 is considered as target for point-of-care diagnostic test
different cut-off levels for MMP-8 detection should be considered for smokers and non-
smokers (Leppilahti et al. 2014a). When biomarkers in saliva samples were detected and
compared with periodontal health status regarding smoking as dichotomous yes-no parame‐
ter, in smokers’ saliva concentration of IL-8 and MMP-8/TIMP-1 ratio were lower than in non-
smokers, and salivary MMP-8 had a borderline p-value significantly lower in smokers
(Rathnayake et al. 2013a). Possible explanation was considered to be the lower GCF flow of
smokers, but also that the effect of smoking on periodontal inflammatory cells is reflected in
saliva. In another study salivary concentration of MMP-8 differentiated periodontitis patients
from controls, but in periodontitis patients who were smokers this difference was lost;
however, the combination of MMP-8 and ICTP and the MMP-8/TIMP-1 ratio differentiated
periodontitis cases from controls suggesting, that a combination of biomarkers could be useful
when saliva is used as diagnostic sample material (Gursoy et al. 2010).
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3.2. Smoking, MMP-8 and elastase levels in early periodontitis and their clinical relevance
In the study of adolescents Heikkinen et al. (2010) observed that smoking associated the lower
levels of MMP-8 and PMN-leukocyte elastase (figure 1. and 2.) and the effect was strengthened
by increased pack-years. However, 15% of adolescents in this birth cohort study seemed to
have signs of early periodontitis (Heikkinen 2011). Salivary MMP-8 values were associated
with BOP and suggestively with deep pockets in the non-smoking teenage boys. In adults
MMP-8 has shown to be a key biomarker during early stages of periodontal diseases (Ramseier
et al. 2009). Clinically smoking reduces the signs of gingivitis (Kumar and Faizuddin, 2011)
masking periodontal diseases, and thus smokers have less observed signs of gingival inflam‐
mation, in adolescents as well as in adults, aggravating the diagnostics of periodontal disease.
It is important that patients receive a proper periodontal diagnosing as part of their regular
dental examination. Early diagnosis of periodontal disease could enable a successful thera‐
peutic outcome, by reduction of etiologic factors such as smoking and by establishing perio‐
dontal therapy and maintenance protocol. Further, this might prevent the recurrence and
progression of disease and reduce the incidence of tooth loss (Kumar et al. 2012). Recently
Nhawator et al. (2014) demonstrated that neutrophil collagenase-2 lateral flow chair-side
(point-of-care) immunoassay analysed from mouth rinse had a high sensitivity for at least two
sites with BOP and two sites with periodontal pockets but a lower relationship for single-site
pockets and BOP. Further studies are needed to find out the clinical relevance for this test as
a screening tool in adolescents finding early periodontitis as well as for adults taking account
the effect of confounders such as smoking into inflammatory biomarkers.
Figure 1. Salivary MMP-8 median values corresponding smoking and sex in adolescents. CI 95%s for male non-smok‐
ers, male smokers, female non-smokers and female smokers are 135.08-220.20 ug/l, 86.20-173.22 ug/l, 145.16-215.33
ug/l, 136.72-230.68 ug/l, respectively.
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Figure 2. Salivary elastase median values corresponding smoking and sex in adolescents. CI 95%s for male non-smok‐
ers, male smokers, female non-smokers and female smokers are 8.75-13.63 x 10 exp-3 ΔOD405/h, 4.75-9.25 x 10exp-3
ΔOD405/h, 8.75-15.25 x10exp-3 ΔOD405/h, 6.63 -17.25 x10exp-3 ΔOD405/h, respectively
3.3. Predictive value of oral fluid MMP-8
It should be noted that MMP-8 levels in oral fluid possess a predictive value (Sorsa et al.
2010, Munjal et al. 2007, Prescher et al. 2007, Kraft-Neumärker et al. 2012, Leppilahti et al.
2014a,b). In this context, periodontitis patients were examined and followed over a course of
12 months at 2 month intervals. In these patients it was possible to clearly differentiate “stable
sites” from “unstable” sites.
• “Stable sites”: Improvement in pocket depth (PD) and attachment loss (AL) were continu‐
ously preserved after treatment, similarly the GCF MMP-8 values were and remained
consistently low.
• “Unstable sites”: No improvement or only temporary improvement in PD and AL were
found, in parallel GCF MMP-8 values only improved shortly after treatment, followed by
an immediate re-increase in the MMP-8 values.
Furthermore, Reinhardt et al. (2010) and Leppilahti et al. (2014a) demonstrated that increases
in GCF MMP-8 during the periodontal maintenance are associated with increased odds of
subsequent periodontal attachment loss and compromised treatment outcome. Overall, these
authors concluded that elevated biomarkers of inflammation and bone resorption identify
patients vulnerable to progressive periodontitis.
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3.4. Elastase, protease inhibitors and sICAM-1
Elastase is another important neutrophil originating proteolytic enzyme. Contradicting
findings about elastase activity in GCF of smokers compared with non-smokers with perio‐
dontitis have been reported, however: significantly higher mean levels of neutrophil elastase
activity in smokers’ than non-smokers’ sites with matching PD has been detected (Söder
1999), but on the other hand lower concentrations of functional elastase in smokers’ than in
non-smokers’ GCF has also been found (Alavi et al. 1995). This finding led Alavi et al. (1995)
to the hypothesis that smokers’ neutrophils may release elastase prior to reaching the perio‐
dontal tissues for example during passing through the lungs, or possibly a greater proportion
of the elastase is bound to substrate and remains undetected which may complicate the
diagnostic value of GCF elastase in smokers.
Smoking possibly intervenes in the levels of protease inhibitors α2-macroglobulin (α2-MG)
and α1-antitrypsin (α1-AT), which may be one mechanism by which smoking can affect the
inflammatory process. In severe periodontal lesions of smokers significantly lower concen‐
trations and total amounts of GCF α2-MG as well as significantly lower total amounts of α1-
AT were found. These findings lead to conclusion that decreased local levels of these inhibitors
may result in increased tissue damage due to increased activity of elastase and collagenase
(Persson et al. 2001).
A soluble form of intercellular molecule-1 (sICAM-1) is known to be elevated in smokers’ blood
compared with non-smokers (Koundouros et al. 1996). Conversely, in smokers with perio‐
dontitis GCF sICAM-1 is significantly lower compared with non-smokers (Fraser et al. 2001).
Based on this finding Fraser et al. (2001) hypothesised that sICAM-1 molecules possibly bind
to sequestrated neutrophils in periodontal microvasculature and provoke an inappropriate
endogenous protease release contributing to periodontal destruction in the vicinity of the
gingival microvasculature.
3.5. Cytokines
Bacterial products stimulate monocytes, macrophages and lymphocytes as well as resident
fibroblasts and endothelial cells to secrete pro-inflammatory and immunoregulatory cyto‐
kines, which control cell growth and differentiation. Bacteria further stimulate chemokines
and pro-inflammatory cytokines or subdue with anti-inflammatory cytokines and interferons
the inflammation and regulate the development of the antimicrobial immunity in cooperation
with antigen presenting cells (Julkunen et al. 2003). Smoking appears to affect normal balance
of several cytokines, which are described as local hormones or cell-to-cell messengers.
Especially the reduction of chemokines in smokers has been regarded to contribute to weak‐
ened neutrophil chemotaxis and migration to the site of inflammation in spite of the existing
leukocytosis (Palmer et al. 2005).
In earlier studies increased levels of tumour necrosis factor (TNF) -α but decreased levels of
IL-6 and IL-1β were detected in GCF of smoking periodontitis patients compared with non-
smokers especially with tendency towards higher TNF-α levels in sites with an inferior
treatment outcome (Boström et al. 1998a, 1999, 2000). Former smokers have also been reported
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to exhibit significantly higher GCF levels of TNF-α than non-smokers (Boström et al. 1998b).
Parallel effect of smoking has been detected on GCF IL-10 both prior to as well as after
periodontal treatment compared with non-smokers (Goutoudi et al. 2004).
Smoking seems to decrease the mean levels of GCF IL-1α concentrations significantly but does
not affect mean total protein concentration (Petropoulos et al. 2004). In this study by Pertro‐
pulos et al. (2004) neutrophil numbers were not significantly different between smokers and
non-smokers suggesting that the reduced IL-1α concentration of smokers may be independent
of any effect of smoking on neutrophil chemotaxis, and smoking may directly inhibit IL-1α
production. Thus GCF IL-1α may be derived from the inflamed tissues rather than being locally
produced by neutrophils in pocket.
Recently multiplex immunoassays have been used to analyse simultaneously multiple GCF
cytokines. A comprehensive investigation by a multi-bead array assay facilitated the charac‐
terization of 22 GCF cytokines, which were studied with respect to possible alterations in host
response caused by smoking (Tymkiw et al. 2011). Quantities of pro-inflammatory cytokines,
chemokines and regulators of T-cells and NK cells were found to be affected by smoking.
Healthy sites of smoking periodontitis patients showed significantly less IL-6 and IL-12 than
similar sites of non-smoking patients. In addition to these, smokers’ periodontitis sites showed
also significantly lower quantity of IL-1α. Of chemokines IL-8, IL-10, monocyte chemoattrac‐
tant protein (MCP)-1, macrophage inflammatory protein (MIP) -1α and RANTES were
detected in lower amounts both from healthy and diseased sites of smoking periodontitis
patients compared with similar sites in non-smokers suggesting that low chemokine response
leads to inability to recruit inflammatory and immune cells and further to ineffective defence.
This may have a major role in the pathogenesis of periodontitis in smokers. Also IL-7 and IL-15,
regulators of T-cells and NK cells, showed a decrease in smokers compared with non-smokers
(Tymkiw et al. 2011).
However, another study also utilizing a multiplex immunoassay concluded that there were
no correlations between GCF levels of MIP-1α and RANTES and the smoking status suggesting
that at the local level smoking is not a major determinant of the CC group chemokine concen‐
trations in GCF, and that the determinant is the level of local inflammation (Haytural et al.
2014). Another contradicting finding was detected by analysing MCP-1 with enzyme linked
immunosorbent assay (ELISA), where MCP levels in GCF were highest in smokers with
periodontitis when compared with non-smoking periodontitis patients and healthy controls
(Anil et al. 2013), showing the possible effect of the analyse method on the results.
3.6. sRANKL and OPG
Soluble receptor activator of nuclear factor κ B ligand (sRANKL), its cellular receptor RANK
and osteoprotegerin (OPG), a protein, which binds to RANKL blocking its interaction with
RANK, are the regulators of bone formation and resorption (Tang et al. 2009). Periodontitis
patients compared with healthy controls exhibit higher expression of RANKL in gingival
tissues and GCF, which associates especially with active sites (Vernal et al. 2004). RANKL:OPG
ratios may be increased in GCF of periodontitis patients (Bostanci et al. 2007). In current and
former smoking periodontitis patients GCF OPG concentrations were lower compared with
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never smokers, and finding was opposite concerning the sRANKL concentration (Tang et al.
2009). Consequently, the sRANKL:OPG ratio also appeared to be higher in current and former
smokers but the finding was not statistically significant. Interestingly, when pack-years were
included in the analysis, OPG concentration decreased with increasing pack years and also the
sRANKL:OPG ratio was significantly higher in the high pack-years group being significant
also in the multivariate analysis (Tang et al. 2009). An increased lifetime exposure above a
minimum threshold of cigarette smoking was required for this pattern. This finding is
supported by earlier results where the combination of lipopolysaccharide and nicotine were
shown to decrease OPG production in osteoblasts in a dose dependent manner (Tanaka et al.
2006) and where periodontal ligament fibroblasts and epithelial cells directly exposed to
nicotine decreased their overall protein synthesis (Giannopoulou et al. 2001; Chang et al.
2002). This may lead to increased sRANKL:OPG ratio in smokers and further cause imbalanced
tissue homeostasis and consequent tissue degradation (Tang et al. 2009).
4. Systemic inflammation and salivary biomarkers
Analyzing and utilization of inflammatory and disease specific biomarkers in saliva could offer
an attractive solution for the diagnosis of different systemic diseases (Rathanayake et al. 2013b).
The composition of saliva mainly originates from blood but in the salivary glands active
transport and secretion mechanisms may change the saliva composition as the organic
components of glandular specific saliva are derived from protein synthesis and are stored
within the acinar cells (Kaufman & Lamster (2002), Malamud 1992). Nevertheless, saliva could
be an alternative to blood as a biological fluid for analysis in diagnostic and prognosis purposes
since the collection of saliva is non-invasive and is a plausible method. Systemic inflammation
leads to the relief of pro-inflammatory mediators from immune cells, and the activation of the
innate immune system. An increasing number of specific molecular markers for different
conditions, such as cancer, cardiovascular disease (CVD), rheumatoid arthritis (RA), diabetes
and human immunodeficiency virus has been identified (Boyle et al. 1994, Hu et al. 2008,
Zhang et al. 2010).
4.1. Cardiovascular disease
High sensitive methods for biomarker detection have been developed since year 2000. There
are certain biomarkers released due to a myocardial injury caused by myocardial ischemia-
and necrosis, such as cardiac troponins I (TnI) and T (TnT), creatine kinase-MB (CK-MB), total
creatine kinase, myoglobin, and lactate dehydrogenase (Mueller et al. 2013, Tiwari et al.
2012). Analysis of cardiac TnI and TnT are considered as the golden standard for diagnosis of
acute myocardial infarction (AMI) as they are tissue specific for the myocardium (Tiwari et al.
2012). There are few earlier publications that have revealed correlations between serum and
salivary biomarkers of CVD (Mirzaii-Dizgah et al. 2012, Quellet-Morin et al. 2011). The Tn I
levels reaches its peak within 10–14 hours followed to an AMI, and according to the previous
studies Tn I levels could be detected in saliva within 24 hours of onset of AMI (Mirzaii-Dizgah
& Riahi 2013). A bedside saliva-based Nano-Biochip test together with electrocardiogram
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could provide prompt screening method for AMI patients in prehospital stage and the
investigators of this study were able to detect elevated salivary levels of creatine kinase-MB,
myoglobin, TnI and TnT, C-reactive proteins (CRP), TNF-α, MMP-9 and myeloperoxidase
from AMI patients (Floriano et al. 2009).
In the study of Palm et al. (2013) on patients with acute ischemic stroke, systemic and local
inflammatory markers were analysed of patients saliva. In this study, controls had enhanced
levels of salivary MMP-8, MPO and IL-1β compared to the patients, since the control group
was suffering from ongoing periodontal disease and the patients more often had evidence of
end-stage periodontitis with edentulism and missing teeth. They also had higher levels of
serum MMP-8 and MPO. Additional longitudinal studies are needed, however, to check the
potential of salivary biomarkers associated in ischemic stroke.
4.2. Diabetes
There are a few studies concerning the detection of inflammatory biomarkers in saliva of
patients with diabetes. Goodson and co-authors reported that in a child population unstimu‐
lated saliva samples were analysed and the salivary levels of CRP, insulin and leptin were
remarkably higher in obese children compared with healthy normal weight children (Goodson
et al. 2014). In a cross sectional study on 451 patients elevated salivary levels of MMP-8 were
found among diabetes patients (Rathnayake et al. 2013). Salivary N-acetyl-β-D-hexosamini‐
dase (HEX) which is associated with type I diabetes was found to be significantly increased in
children with type 1 diabetes compared with healthy children (Zalewska-Szajda et al. 2013a).
4.3. Rheumatoid arthritis
The disease pattern of RA is similar to periodontal disease. Systemic inflammatory biomarkers
from different chronic inflammatory conditions, such as RA could thus appear in saliva. There
are few studies in this area, but when conducting an exploration of inflammatory biomarkers
in RA patients, the periodontal status and the anti-TNF-α therapy taken by these patients need
to take in to consideration. Salivary IL-1β was found to be significantly higher in the RA
patients who were not on anti-TNF-α therapy compared with RA patients receiving anti-TNF-
α therapy (Zalewska-Szajda et al. 2013b). Salivary exoglycosidases for detection of salivary
gland involvement in RA patients were studied, in xerostomic RA group salivary β-glucuro‐
nidase was found to be significantly higher compared with healthy controls but the activity of
salivary N-acetyl-β-hexosaminidase and β-glucuronidase was significantly lower than in
xerostomic hyposalivary RA patients (Zalewska-Szajda et al. 2013b).
4.4. Cancer
To use salivary biomarkers to detect on / monitor all types of cancer is a growing research field
in salivary diagnostics. The most common malignant neoplasm of the oral cavity is oral
squamous cell carcinoma (OSCC). Patients with OSCC indicated that a specific marker of
oxidative stress, malondialdehyde (MDA) in saliva was a better diagnostic tool as MDA in
blood (Rasool et al. 2014). Salivary IL-8 levels seem to be higher in patients who had experi‐
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enced tumour diseases (Rathnayake et al. 2013a,b). To detect head and neck squamous cell
carcinoma (HNSCC) microRNAs (miRNAs) of saliva was used, and the results showed that
miR-9, miR-134 and miR-191 were differentially expressed between saliva from HNSCC
patients and healthy controls. Additionally, the authors suggested that these saliva-derived
miRNAs may serve as novel biomarkers to reliably detect HNSCC (Salazar et al. 2014).
There are number of cytokines and chemokins involved in the cancer progression, such as
interferon-gamma (IFN-γ), TNF-α, IL-1β, transforming growth factor-beta-1 (TGF-β1),
epidermal growth factor (EGF), IL-6 and -8, vascular endothelial growth factor (VEGF),
interleukins-4 and -10, tumour necrosis factor (TNF) and endothelin. Saliva based testing of
these biomarkers is promising depending on the methods of analysis (Prasad & McCullough
2013). About 5 % of all cancers of the head and neck are salivary gland carcinomas (SGCs).
Thus there is a need to develop new molecular biomarkers for early diagnosis and to improve
the diagnosis of SGCs. Further research in this is required.
To identify disease specific molecular biomarkers in whole saliva is challenging. There are
certain biomarkers found in saliva of high sensitivity and specificity, particularly in oral
diseases, such as periodontal disease and oral cancer. There are factors that have an influence
for the expression and release of biomarkers, such as their intracellular location, the size of the
proteins, and the characteristics of the local biological fluid flow. The type of saliva used for
diagnostic purpose to detect systemic conditions has an impact. In this regard unstimulated
saliva reveals more information than stimulated saliva since unstimulated saliva contains
higher concentrations of diagnostic biomarkers. High sensitivity and sophisticated methods
and techniques are required for valuable outcome of the analyses of saliva samples.
5. Conclusion remarks
Inflammatory saliva and GCF biomarkers can be used as an aid in periodontal diagnostics, but
there is a need to define the range of physiological levels and cutoff for pathological bursts of
periodontitis progression. However, using just one definite cutoff point or merely one
biomarker is not rational for adults or adolescents. Adolescence might have certain character‐
istics with different cutoff points compared to adults. The clinical use of salivary biomarkers
to identify systemic conditions is another interesting area for developing non-invasive
screening and diagnostic procedure. This might be the main goal for saliva research but in this
regard it is important to consider the influence of oral health conditions which may confound
the utility of the biomarkers. Modifying factors, such as smoking and pregnancy also should
be taken into account when interpreting the results of the oral fluid inflammatory biomarkers.
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